Blood Test Granted Breakthrough Status, To Be Tested in Trial
The FDA has prioritized review of C2N’s blood test for amyloid-β. A pivotal clinical trial will correlate the test with amyloid PET scans.
264 RESULTS
Sort By:
The FDA has prioritized review of C2N’s blood test for amyloid-β. A pivotal clinical trial will correlate the test with amyloid PET scans.
An interim analysis predicted the antibody would not slow Alzheimer’s progression; a crenezumab trial in autosomal-dominant AD is continuing.
Reducing systolic blood pressure staves off cognitive decline, but what about dementia?
A periodontal pathogen found in human brains triggers AD pathology in mice. Will an antibiotic stave off dementia?
Frail people may be more likely to have Aβ plaques and neurofibrillary tangles; when they do, they are more likely to have dementia. Physical activity correlated with better global cognition, regardless of brain pathology.
Studies in mice and humans show that sleep suppresses extracellular tau and slows its spread.
Ever wonder why it’s so easy to nod off in a hammock? Turns out swaying back and forth improves sleep and even enhances memory in people.
Are high-molecular-weight, multi-protease complexes cellular Aβ factories?
In familial Alzheimer’s disease, rise in NfL in the blood precedes disease onset by 16 years.